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Idiopathic pulmonary ﬁbrosis (IPF) is a fatal disease that is unresponsive to
current therapies and characterized by excessive collagen deposition and sub-
sequent ﬁbrosis. While inﬂammatory cytokines, including interleukin (IL)-6,
are elevated in IPF, the molecular mechanisms that underlie this disease are
incompletely understood, although the development of ﬁbrosis is believed to
depend on canonical transforming growth factor (TGF)-b signalling. We
examined bleomycin-induced inﬂammation and ﬁbrosis in mice carrying a
mutation in the shared IL-6 family receptor gp130. Using genetic complementa-
tion, we directly correlate the extent of IL-6-mediated, excessive Stat3 activity
with inﬂammatory inﬁltrates in the lung and the severity of ﬁbrosis in
corresponding gp130
757F mice. The extent of ﬁbrosis was attenuated in B
lymphocyte-deﬁcient gp130
757F;mMT
 /  compound mutant mice, but ﬁbrosis
still occurred in their Smad3
 /  counterparts consistent with the capacity of
excessive Stat3 activity to induce collagen 1a1 gene transcription independently
of canonical TGF-b/Smad3 signalling. These ﬁndings are of therapeutic
relevance, since we conﬁrmed abundant STAT3 activation in ﬁbrotic lungs from
IPF patients and showed that genetic reduction of Stat3 protected mice from
bleomycin-induced lung ﬁbrosis.
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Tissue ﬁbrosis results from excessive and progressive scarring
associated with destruction of normal tissue architecture and
structure, and ultimately compromises organ function (Wilson
& Wynn, 2009; Wynn, 2007). The clinical challenge of treating
ﬁbrotic diseases is exempliﬁed by idiopathic pulmonary ﬁbrosis
(IPF), a heterogeneous disease unresponsive to therapy and
fatal in outcome (Knight et al, 2003; Wilson & Wynn, 2009).
Although the molecular mechanisms underlying initiation of
IPF remain largely unknown, ﬁbrosis is thought to arise from
excessive tissue response to injury. Accordingly, effort has
concentrated on the genetic dissection of steps that collectively
govern normal wound healing processes and that enable re-
epithelialization and extracellular matrix production to subside
upon re-establishment of tissue homeostasis. Besides epithelial
proliferation, differentiation and regeneration, these processes
also involve stromal components, which are activated as part of
the ensuing inﬂammatory response (Wilson & Wynn, 2009).
In IPF, epithelial injury is followed by pathologic ﬁbrotic
repair in distinct cellular foci within the lung parenchyma
comprising proliferating ﬁbroblasts and subepithelial myoﬁ-
broblasts that are associated with excessive deposition of
extracellular matrix proteins, including type I collagen (Cool
et al, 2006; Maher et al, 2010; Moodley et al, 2003). Activation
of these myoﬁbroblasts correlates with increased levels of
interleukin (IL)-1b, IL-4, IL-13, IL-17, and other inﬂammatory
cytokines and is believed to be mediated by transforming
growth factor (TGF)-b (Wilson & Wynn, 2009; Wilson et al,
2009). TGF-b and its canonical downstream signalling molecule
Smad3 are central to the development and progression of
ﬁbrosis as elevated levels of TGF-b are sufﬁcient to reproduce
organ ﬁbrosis in animal models, stimulate ﬁbroblast differ-
entiation and epithelial-to-mesenchymal transformation, and
the observation that Smad3-deﬁciency confers resistance in
mouse models of IPF (Bonniaud et al, 2004; Zhao et al, 2002).
During inﬂammation, stromal cells and those of the
macrophage/monocyte lineage release inﬂammatory cytokines
oftheIL-6family,whicharethought topromoteﬁbrosisthrough
Erk1/2signalling-associated ﬁbroblastproliferation(Moodleyet
al,2003)andtheinductionofaﬁbroticresponsethatismediated
by various TGF-b family of ligands (Ogata et al, 2006). Several
members of the IL-6 cytokine family, which is characterized by
the shared use of the common gp130 receptor subunit, have
been implicated in pulmonary ﬁbrosis. Transgenic overexpres-
sion of IL-11 or Oncostatin M (Osm) in mice, for instance,
promotes lung scarring with striking histo-pathological simila-
rities to that observed in human disease (Bamber et al, 1998;
Kuhn et al, 2000). Meanwhile, overexpression of IL-6 is a
common ﬁnding in bronchoalveolar lavage (BAL) ﬂuid of IPF
patients (Mozaffarian et al, 2008), where IL6 gene polymorph-
isms segregate with disease severity (Pantelidis et al, 2001).
Meanwhile, activation of the latent transcription factor Stat3,
one of the signalling molecules engaged by gp130, has been
proposed to affect ﬁbrosis in skin and liver (Ghazizadeh et al,
2007; Ogata et al, 2006), albeit with contradicting outcomes
(Mair et al, 2010). These observations therefore leave the
mechanisms unresolved by which the wide-spread expression
of gp130 on epithelial, stromal and hematopoietic cells, and the
individual intracellular molecular components engaged by
gp130 contribute to ﬁbrosis and whether this response requires
canonical TGF-b/Smad3 signalling (Knight et al, 2003).
In this study, we use gp130 mutant mice with either
deregulated Stat1/3 or Erk1/2-signalling to assess susceptibility
to bleomycin administration as a widely used model that
recapitulates epithelial injury-induced lung ﬁbrosis (Moeller et
al, 2008). We found that ligand-dependent excessive Stat1/3
activation, either in the hematopoietic or stromal compartments
of gp130
757F mice (Jenkins et al, 2005a), increased bleomycin-
induced ﬁbrosis in an IL-6 dependent manner, and that systemic
ablation of Il6 or impairment of gp130-mediated Stat3 activa-
tion, attenuated the ﬁbrotic response. Importantly, gp130-
mediated lung ﬁbrosis occurred independently of canonical
TGF-b signalling in Smad3-deﬁcient mice, but required mature
B lymphocytes and correlated with parenchymal accumulation
of B-cell containing foci. With the prevalence of excessive Stat3
activation in lungs of IPF patients and the capability of
therapeutically targeting components of the gp130 signalling
cascade, our ﬁndings are likely to be of clinical relevance.
RESULTS
Excessive fibrotic response in mice with exaggerated
IL-6-dependent Stat3 hyperactivation
To mimic the development of human inﬂammation-associated
lung ﬁbrosis in mice, we trans-nasally administered bleomycin
to gender-matched mice (8–12 weeks of age) harbouring gp130
mutations that bias intracellular signalling either towards the
Stat1/3 or Erk1/2 signalling pathways in gp130
757F mice or
gp130
DStat mice, respectively (Tebbutt et al, 2002) (Supporting
Information Fig S1). Compared to wild-type (gp130
wt) mice,
bleomycin-challenged gp130
757F mice showed extensive
changes to their lung architecture, including consolidation of
airspaces, thickened alveolar septae, inﬂammation and epithe-
lial dysplasia (Fig 1). In contrast, gp130
DStat mice were
completely protected from pulmonary ﬁbrosis. We corroborated
these observations by measuring hydroxyproline content of
lungs as an established marker of collagen deposition 14 and
30 days following bleomycin challenge, as well as by assessing
Col1a1 transcription in lungs of these mice (Fig 2A and B). We
have previously shown that gp130
DStat, gp130
wt and gp130
757F
mice simultaneously comprise an allelic series for increasing
gp130-mediated Stat1/3 signalling (attenuated in gp130
DStat
and excessive in gp130
757F mice) and for Erk1/2 signalling
(excessive in gp130
DStat and attenuated in gp130
757F mice)
(Jenkins et al, 2005a; Tebbutt et al, 2002). This was conﬁrmed
byexaminingtheabundanceoftranscriptionallyactive,tyrosine
phosphorylated form of Stat3 (pStat3) in lung ﬁbroblasts
obtained from gp130
757F, gp130
wt and gp130
DStat mice treated
with IL-6 for 0–180min (Supporting Information Fig S2A). The
molecular rationale underpinning the reciprocal relationship
between activation of the Stat1/3 and Erk1/2 signalling arises
from the observation that the negative regulatory Socs3 protein
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the phosphorylated tyrosine residue in position 757 in mouse
(759 in human) gp130 (Ernst & Jenkins, 2004).
Inorder todissectthecontribution oftheindividualpathways
engaged by gp130 to the ﬁbrotic response, we systemically
restricted the pool of Stat3 or Stat1 available for activation using
compound gp130
757F mice (Ernst et al, 2008). Upon reduction
of excessive Stat3 activation observed in compound
gp130
757F mice to levels more comparable to those observed
in gp130
wt mice, we detected a similar ﬁbrotic response between
gp130
757F;Stat3
þ/  and gp130
wt mice 30 days after challenge
(Figs 1 and 2A,B). However, complete Stat1 ablation in
gp130
757F;Stat1
 /  mice only provided partial protection from
ﬁbrosis (Supporting Information Fig S2B and C). These genetic
observations imply that the enhanced ﬁbrosis observed in
gp130
757F mice mediated by increased Stat3 activation exceeds
that mediated by genetic ablation of Stat1 expression (Walters
et al, 2005) and suggest a direct relationship between the
severity of the ﬁbrotic response and the extent of gp130-
mediated Stat3 signalling. Consistent with this, we detected
excessive Col1a1 luciferase (Col1a1-luc) reporter activity in
gp130
757F embryonic ﬁbroblasts in response to stimulation with
the pan-gp130 designer cytokine HYPER-IL-6 (Fig 2C). Since
HYPER-IL-6 activates gp130 independently of the ligand binding
www.embomolmed.org Research Article
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Figure 1. Gp130 cytokine family-mediated Stat3
signalling determines susceptibility to fibrosis.
Masson’s trichromestain of lungs from gp130
wt(wt),
gp130
757F (757F), gp130
DStat (DStat) or
gp130
757F;Stat3
þ/  (757F;Stat3
þ/ ) mice 30 days
after saline or bleomycin treatment. Images are
representative ofthreemiceforeachgenotype.Scale
bar¼500mm( ¼100mm insets).
EMBO Mol Med (2012) 4, 939–951  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 941IL-6 receptor a-subunit (Fischer et al, 1997), this excludes the
possibility that our observed results reﬂect potential differences
in endogenous IL6 receptor expression between the different
genotypes. We measured mRNA levels of the IL-6 family
members Il6, Il11 and Osm in the lungs of wt and gp130
757F mice
3 days after bleomycin challenge and found that in bleomycin-
challenged lungs of gp130
757F mice, Il6 mRNA remained
selectively elevated 14 days later (Fig 2D and Supporting
Information Fig 2D). Trans-nasal administration of HYPER-IL-6
promoted Col1a1 gene transcription profoundly in lungs of
gp130
757Fmicerelativetolungsofgp130
757F;Stat3
þ/ orgp130
wt
mice (Fig 2E). The potential role of IL-6 family molecules
directly promoting lung ﬁbrosis was further supported by our
observation that genetic ablation of Il6 in gp130
757F;Il6
 /  mice
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Figure 2. Gp130-mediated Stat3 signalling stimulates collagen accumulation and collagen transcription.
A. Percent change in collagen content in lung homogenates between saline and bleomycin-treated wild-type (wt), gp130
757F (757F), gp130
DStat (DStat) and
gp130
757F;Stat3
þ/  (757F;Stat3
þ/ ) mice 14 and 30 days after bleomycin challenge. Data were normalized to mean collagen content of syngeneic saline
controls and expressed as percentage change. n 4 mice. The range of collagen between saline and bleomycin treated mice was 3.219–44.710mg.
B. qPCR analysis of Col1a1 mRNA expression in lung homogenates 30 days after bleomycin treatment and normalized to Gapdh expression. n¼4 mice.
C. HYPER-IL-6-dependent stimulation of Col1a1-luc reporter activity in transiently transfected embryonic fibroblasts. Data were normalized to Renilla luciferase
activity and expressed as the relative change in relative luminescence units (RLU) compared to untreated syngeneic cells. n¼3 mice.
D. qPCR analysis of Il6 mRNA expression in lung homogenates from mice 3, 14 and 30 days after and before bleomycin challenge and control mice(0). n¼4 mice.
E. qPCR analysis of Col1a1 mRNA expression in lung homogenates following 2 weeks of trans-nasal HYPER-IL-6 delivery. Col1a1 signals are expressed relative to
the Col1a1/18S ratio of HYPER-IL-6 challenged wt mice. n¼4 mice. All data are expressed as mean SEM with
 p<0.05,
  p<0.01 using Bonferroni multiple
comparisons test.
942  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2012) 4, 939–951ameliorated the excessive ﬁbrotic responses induced in
bleomycin challenged gp130
757F mice (Supporting Information
Fig S3A and B).
Excessive fibrotic response in gp130
757F mice depends on
mature B lymphocytes
Injury-dependent induction of cytokines primes the subsequent
inﬂammatory response that precedes the development of
pulmonary ﬁbrosis (Wilson & Wynn, 2009). We therefore
analysed BAL ﬂuid from bleomycin-challenged mice and
observed augmented cytokine accumulation, in particular of
IL-1, IL-6, IL-13, and GCSF, in gp130
757F mice when compared to
gp130
wt, gp130
757F;Stat3
þ/ ,o rgp130
DStat mice (Supporting
Information Fig S4A and B). However, at the height of the
inﬂammatory response 3 days after bleomycin administration
(Moeller et al, 2008; Wilson & Wynn, 2009), there was no
correlationbetweenthenumberofinﬂammatorycellscontained
within BAL ﬂuid of bleomycin-challenged mice (Fig 3A and
Supporting Information Fig 4C) and extent of ﬁbrosis 30 days
later (Figs 1 and 2A and Supporting Information Fig 3A and B).
Foci of inﬂammatory cells within the lung parenchyma
were most prominent in gp130
757F mice compared to all other
genotypes of mice consistent with the severe ﬁbrosis observed
in these mice (Fig 3B and Supporting Information Fig S5A).
Collectively, these data suggest that attenuated Stat3 activation
mayenableegressionofinﬂammatorycellsintoBALﬂuid,while
excessive Stat3 activity may promote their retention in the lung
parenchyma.
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Figure 3. Increased lymphocytes are associated with inflammation and lung fibrosis.
A. Changes to cell numbers in BAL fluid of wild-type (wt), gp130
757F (757F), gp130
DStat (DStat) and gp130
757F;Stat3
þ/  (757F;Stat3
þ/ ) mice 3 days after
bleomycin administration relative to saline-treated mice of the same genotype. n 4 mice. MØ, macrophages; PMN, polymorphonuclear cells and LYM,
lymphocytes.
B. Distribution of inflammatory cells in foci within the lung parenchyma of mice 3 days after bleomycin treatment. Cell types were identified by histological
appearance (PMN) or immunohistochemical staining for F4/80 (MØ), or CD3 and B220 (LYM). n 4 mice.
C. Femalewtor757Fmice(n>3pergroup)werereconstitutedwithbonemarrowfrom757F,wtorDStatmiceandlungswerecollectedchallenged21daysafter
bleomycin or saline administration. Bars indicate percent change in collagen content in lung homogenates between saline and bleomycin treated mice. The
range of collagen between saline and bleomycin treated mice was 7.089–31.658mg. Empty bars show lung collagen levels in bleomycin challenged mice that
have not undergone bone marrow transplant.
D. qPCR analysis of Col1a1 mRNA expression in lung homogenates 30 days after bleomycin challenge of wt, 757F, gp130
757F;Rag1
 /  (757F;Rag1
 / )a n d
gp130
757F;mMT
 /  (757F;mMT
 / ) mice. Col1a1 signals were normalized to 18S and expressed relative to saline-treated mice of the same genotype. n¼4
mice. All data are expressed as mean SEM with
 p<0.05,
  p<0.01 and
   p<0.001 using Bonferroni multiple comparisons test.
EMBO Mol Med (2012) 4, 939–951  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 943Since bleomycin-induced lung ﬁbrosis depends on the
preceding inﬂammatory response (Moeller et al, 2008), we
performed adoptive bone marrow transfer experiments to
comparethecontributionstodiseasebetweenthehematopoietic
and the parenchymal compartment. We excluded a major
effect from the irradiation process, since the ﬁbrotic response
remained indistinguishable between non-irradiated and non-
reconstituted bleomycin challenged gp130
757F or gp130
wt mice
and their syngeneically reconstituted counterparts (Fig 3C).
However, in reconstituted gp130
757F hosts, but not in gp130
wt
hosts, we observed a gradual attenuation of bleomycin-induced
hydroxyproline accumulation that correlated with the extent by
which gp130-dependent Stat3 activation could occur in donor
cells (i.e. excessive in gp130
757F and attenuated in gp130
DStat
bone marrow cells). Furthermore, when reconstituted with
bone marrow proﬁcient for gp130-dependent Stat3 signalling
(i.e. gp130
757F or gp130
wt cells), gp130
757F hosts were more
susceptible to ﬁbrosis than gp130
wt hosts. Collectively, these
observations suggest that excessive gp130-mediated Stat3
signalling in the lung parenchyma of gp130
757F hosts promotes
ﬁbrosis, which is further ampliﬁed by excessive Stat3 signalling
in bone marrow-derived cells.
The striking correlation between focal lymphocytic accumu-
lationinthelungparenchyma ofgp130
757Fmiceandthe severity
of their ﬁbrotic response (Figs 2A and 3B) is consistent with a
role for lymphocytes during development of bleomycin-induced
lung ﬁbrosis and their prominent abundance in ﬁbrotic
tissues of IPF patients with non-speciﬁc interstitial pneumonia
(Keogh & Limper, 2005; Wilson & Wynn, 2009). Indeed,
we observed a profound increase in B220-positive cells
in bleomycin-challenged gp130
757F mice, which persisted for
30 days (Supporting Information Fig S5B and C). Furthermore,
mature lymphocytes exacerbate ﬁbrosis in gp130
757F mice,
since ﬁbrosis in T and B lymphocyte compound-deﬁcient
gp130
757F;Rag1
 /  mice was reduced and comparable to
disease in bleomycin challenged wild-type mice (Supporting
Information Fig S5D). This observation was corroborated at the
level of Col1a1 gene transcription which was similar in wild-
type and gp130
757F;Rag1
 /  mice (Fig 3D). Moreover, we also
observed reduced ﬁbrosis and collagen transcription in
gp130
757F;mMT
 /  compound mutant mice deﬁcient in mature
B lymphocytes. Collectively, our ﬁndings suggest that bone
marrow derived B lymphocytes promote bleomycin-induced
ﬁbrosis in susceptible gp130
757F hosts (Fig 3D and Supporting
Information Fig S5D).
TGF-b response is blunted in gp130
757F mice
The development of experimental ﬁbrosis correlates with
elevated TGF-b levels, which is thought to molecularly link
the activity of inﬂammatory cytokines to the resulting ﬁbrotic
response (Bonniaud et al, 2005; Gauldie et al, 2007). This
concept is supported by the observation that two distinct Smad3
null mutations protect mice from bleomycin-induced lung
ﬁbrosis (Bonniaud et al, 2004; Zhao et al, 2002) as well as TGF-
b-induced lung ﬁbrosis (Bonniaud et al, 2004; Bonniaud et al,
2005). Using recombinant TGF-b1 as a reference, we detected
elevated levels of TGF-b activity in serum from gp130
757F mice
when assayed on NIH3T3 cells expressing the pCAGA12-luc
reporter plasmid that records Smad3-dependent gene
transcription (Supporting Information Fig S6A). However,
when assaying for TGF-b-induced phosphorylation of Smad3
(pSmad3) we observed reduced abundance of this transcrip-
tionally active form of Smad3 in lung ﬁbroblasts from gp130
757F
mice compared to those prepared from gp130
wt, gp130
DStat or
gp130
757F;Stat3
þ/  mice (Supporting Information Fig S6B).
Similarly, the capacity of TGF-b to induce Col1a1 gene
expression was reduced in lung ﬁbroblasts from gp130
757F
mice when compared to those obtained from either gp130
wt or
gp130
757F;Stat3
þ/  mice (Supporting Information Fig S6C),
suggesting that excessive Stat3 activation decreases TGF-b-
responsiveness of primary lung ﬁbroblast from gp130
757F mice.
Indeed, this observation is consistent with our previous ﬁndings
that excessive Stat3 activity blunted TGF-b-induced signalling
(i.e. Smad2 phosphorylation) and transcriptional response (i.e.
pCAGA12-luc activity) in mouse embryo ﬁbroblasts and gastric
epithelium of gp130
757F mice due to enhanced transcriptional
induction of the TGF-b signalling antagonist Smad7 (Jenkins
et al, 2005a).
Fibrosis in gp130
757F mice occurs independently of Smad3
Since gp130
757F mice develop a more profound ﬁbrotic
response to bleomycin despite their attenuated TGF-b
responsiveness, we next determined genetically whether their
enhanced lung ﬁbrosis could occur independently of canonical
TGF-b signalling. We therefore challenged gp130
757F and
gp130
757F;Smad3
 / micewithbleomycin andobserved21days
later in both genotypes of mice a profound ﬁbrotic response
that was characterized by excessive hydroxyproline accumula-
tion and collagen deposition in the pulmonary interstitium
(Fig 4A and B). In gp130
wt mice, however, ablation of Smad3
(Smad3
 / ) reduced bleomycin-dependent lung ﬁbrosis in mice
as previously reported (Bonniaud et al, 2004; Zhao et al, 2002)
when compared to the ﬁbrotic lesions and excessive collagen
deposition observed in Smad3 proﬁcient wild-type mice 30 days
after bleomycin challenge (Fig 4A and B).
To ascertain that excessive Stat3 activation could mediate
bleomycin-induced ﬁbrosis independently of Smad3, we
extended this observation to a physiologically more relevant
setting where excessive Stat3 signalling occurred in gp130
wt
mice in response to prolonged exposure to gp130 cytokines
rather than through engagement of mutant gp130
757F receptors.
Since prolonged exposure of mice to Osm and other gp130-
cytokines promotes excessive collagen production and ﬁbro-
blast proliferation (Mozaffarian et al, 2008; Scafﬁdi et al, 2002),
we transnasally administered a replication-deﬁcient adenovirus
encoding murine Osm to wild-type mice and demonstrated
an increase in transcriptionally active phosphorylated Stat3
(Supporting Information Fig S6D). Furthermore, continuous
exposure of Smad3
 /  mice to Osm induced severe sub-
epithelial and interstitial pulmonary ﬁbrosis 14 days later
that was comparable to the response seen in wild-type mice
(Fig 4C). This was in contrast to Smad3 deﬁciency conferring
protection from bleomycin-induced lung ﬁbrosis in gp130
wt
mice (Fig 4A and B).
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To explore the potential relevance of our ﬁndings in the
gp130
757F mouse model to human IPF, we ﬁrst conﬁrmed
that excessive Stat3 activation in ﬁbrotic lungs of bleomycin
challengedgp130
757F micewasdependentonIL-6by monitoring
expression of the bona ﬁde Stat3 target gene Socs3 (Kidder et al,
2008; Snyder et al, 2008). While we observed an IL-6-
independent transient increase in Socs3 expression 3 days after
the bleomycin challenge (Fig 5A), Socs3 expression remained
elevated up to 30 days only in IL-6-proﬁcient gp130
757F mice
if Stat3 expression was not genetically depleted (i.e. in
gp130
757F;Stat3
þ/  mice). These observations correlated with
our ﬁndings of accumulation of phosphorylated Stat3 within
cells that collectively comprise the ﬁbrotic areas of either
bleomycin-challenged gp130
757F or gp130
wt mice, which also
extended to cells immediately adjacent to the collagenous
deposits (Fig 5B). Next, we retrospectively investigated
STAT3 activation in lung sections from IPF patients that were
clinically diagnosed with usual interstitial pneumonia (IPF-UIP,
Supporting Information Table T1). Since we detected pro-
nounced pSTAT3 staining in the parenchymal cells adjacent to
collagenous foci in these biopsies (Fig 5C), we categorized these
cells by concordant immunoreactivity for pan-cytokeratin
or CD45 as being of epithelial and haematopoietic origin,
respectively. This analysis revealed pSTAT3 nuclear staining in
cells co-expressing pan-cytokeratin in addition to extensive
regions of cells with nuclear pSTAT3 staining that was
discordant with cells staining for pan-cytokeratin or CD45
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Figure 4. Stat3 promotes lung fibrosis and collagen synthesis independent of Smad3.
A. Masson’s trichrome stained sections of lung from gp130
wt (wt), Smad3
 /  (Smad3
 / ), gp130
757F (757F) or gp130
757F;Smad3
 /  (757F;Smad3
 / ) mice
21 days after challenge with bleomycin or saline. Images are representative of n¼3 mice. Scale bar¼500mm( ¼100mm insets).
B. Percent change in collagen content in lung homogenates between saline and bleomycin treated mice of the indicated genotypes 30 days after challenge. n 3
mice. The range of collagen levels between saline and bleomycin treated mice was 4.369–26.48mg. Data are expressed as mean percentage change SEM,
with
 p<0.05 using Bonferroni multiple comparisons test.
C. Masson’s trichrome stained section of lungs from wt (top) or Smad3
 /  (bottom) mice 14 days after trans-nasal delivery of control (left) or Ad-mOsm virus
(right). Images are representative of three mice. Scale bar¼500mm( ¼100mm insets).
EMBO Mol Med (2012) 4, 939–951  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 945Research Article www.embomolmed.org
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946  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2012) 4, 939–951(Fig 5D). These observations are consistent with emerging
reports suggesting that STAT3 activation not only occurs within
inﬂammatory cells associated with ﬁbrotic lesions (Lim et al,
2006; Lim et al, 2009; Ogata et al, 2006), but also may play a
role in non-epithelial cells to exacerbate the wound-healing
responses that are characteristic for IPF lesions.
Genetic restriction of Stat3 signalling ameliorates the fibrotic
response in bleomycin-challenged mice
The potential role of excessive gp130-mediated STAT3 signal-
ling in human IPF prompted us to explore whether reduction of
Stat3 could confer a prophylactic protection from lung ﬁbrosis.
To this end, we reasoned that future therapeutic interventions
may confer a systemic rather than lung-speciﬁc effect on Stat3
activation. We therefore mimicked this situation by testing
the susceptibility of Stat3
þ/  mice to bleomycin-induced lung
ﬁbrosis. Surprisingly, Stat3
þ/  mice were completely protected
from the ﬁbrotic response and associated deposition of collagen
in the lung when compared to wild-type mice (Fig 6A and B).
Indeed, the prophylactic effect afforded by genetic restriction of
Stat3expressionwasmoreeffectivethancompletegeneablation
of IL-6 in mice, which only resulted in partial attenuation of the
severity of bleomycin-induced ﬁbrosis (Fig 6A and B; Saito et al,
2008). These ﬁndings suggest that in addition to IL-6, other
gp130 cytokine family members may contribute to the ﬁbrotic
response and therefore systemic inhibition of gp130/Stat3
signalling may provide additional beneﬁts that are not afforded
through targeting of a single cytokine only.
DISCUSSION
Although a timely resolution of acute inﬂammation in response
to (bleomycin-induced) injury enables restoration of normal
tissue architecture, an unrelenting inﬂammatory response
undermines the healing process and culminates in tissue
ﬁbrosis (Wilson & Wynn, 2009; Wynn, 2007). Previous studies
have attempted to experimentally replicate excessive inﬂamma-
tionby overexpressing inﬂammatory cytokines includingTNF-a
or IL-1b (Kolb et al, 2001; Sime et al, 1998). Here, we provide a
model where the increased sensitivity of mutant gp130
757F
receptors mediates cytokine-dependent Stat3 activation in mice
akin to a smouldering asymptomatic inﬂammation triggered
by prolonged intranasal administration of Osm to wild-type
mice or excessive abundance of IL-6 or OSM associated with the
pathogenesis of ﬁbrosis in IPF patients (Lesur et al, 1994;
Mozaffarian et al, 2008; Xing et al, 1994).
While the exact mechanism of action by which excessive
Stat3 activation promotes ﬁbrosis remains to be further
elucidated, our observation in bone-marrow reconstituted
mice indicates a shared contribution of non-haematopoietic
(most likely pulmonary epithelium and ﬁbroblast) and
haematopoietic cells types. Furthermore, our data also suggests
that excessive Stat3 activation promotes tissue retention of
innateimmunecellsandincreasesthenumbersofimmatureand
mature lymphocytes in gp130
757F mice (Jenkins et al, 2005b).
Consistent with this, others have reported that blocking the
interaction between the Stat3 target gene Icam-1 and lympho-
cytes decreased lymphocyte retention in the normal pulmonary
vasculature (Klemm et al, 2000). Although IL6 is a well
characterized inﬂammatory target gene for TNF-a, and
bleomycin-induced ﬁbrosis is ameliorated in Tnfr
 /  mice
(Ortiz et al, 1998), B cell inﬁltrates also fuel IL-6-mediated
and Stat3-dependent cancer growth following the release
of lymphotoxin (LT) (Ammirante et al, 2010). Intriguingly,
bleomycin-induced ﬁbrosis is not only prevented in
Tnf
 / ;Lta
 /  mice (Piguet et al, 1997), but also depends on
thepresence ofCD19-positiveB-cells inwild-typemice(Komura
et al, 2008). Consistent with these observations, we provide
here genetic evidence that the bleomycin-induced ﬁbrotic
response in gp130
757F mice requires mature B lymphocytes.
This correlates with exacerbated accumulation of B220þ cells
and with enhanced abundance of the Th2 cytokine IL-13 in the
lung, which in itself not only requires Stat3 for its effective
production (Stritesky et al, 2011), but also promotes ﬁbrosis
(Fichtner-Feigl et al, 2006). It is therefore tempting to speculate
that, for instance, the combined activity of LT and TNF-a,
through induction of gp130-activating cytokines, indirectly
promotes Stat3 signalling and the excessive matrix production
that underpins lung ﬁbrosis. This view is consistent with
observations that the lower respiratory tract of IPF patients
shows excessive TNF-a, LT-a and IL-6 expression (Lesur et al,
1994; Pantelidis et al, 2001) and that the ﬁbrotic response
correlates with B lymphocyte accrual in lungs from non-speciﬁc
interstitial pneumonia patients (Keogh & Limper, 2005).
Furthermore, exogenous administration of IL-6 family cytokines
may short-circuit the need for lymphocytes, because in their
absence in Rag1
 /  mice, Osm can promote lung ﬁbrosis
(Mozaffarian et al, 2008). Indeed, IL6-dependent Stat3 activa-
tion also promotes the production of two other potential
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Figure 5. Lung fibrosis is associated with activation of gp130-Stat3 signalling cascade.
A. qPCR analysis of Socs3 mRNA expression in lung homogenates from gp130
wt (wt), gp130
757F (757F); gp130
757F;Il6
 /  (757F;Il6
 / )a n dgp130
757F;Stat3
þ/ 
(757F;Stat3
þ/ ) mice 3, 14 and 30 days after bleomycin challenge or from control mice (0). Socs3 signals were normalized to 18S and expressed relative to
saline-treated mice of the same genotype. n 3 mice. Data are expressed as mean SEM with
 p<0.05 and
  p<0.01 using Bonferroni multiple
comparisons test.
B, C. Adjacent lung sections stained either with Masson’s trichrome or phosphorylated Stat3 (pStat3) of lungs from gp130
wt or gp130
757F mice 30 days after
bleomycinchallenge(B),orfromIPFpatientsdiagnosedwithusualinterstitialpneumonitis(IPF-UIP)(C).Theboxedareasinthemiddlepanelsaremagnified
in the bottom panels showing immunoreactive pStat3 staining associated with fibrotic areas. Images are representative of three mice and four patients,
respectively. Scale bar¼100mm (top and middle panels), ¼20mm (bottom panels).
D. Haematoxylin and eosin (H&E) stained and dual fluorescence immunohistochemical labelled pSTAT3 (red) and pan-cytokeratin (green) or CD45 (green),
respectively, in lung sections from IPF-UIP patients. Scale bar¼100mm (H&E), ¼20mm (immunofluorescence).
3
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miR-21 and the generation of IL-17A-producing cells (Liu
et al, 2010; Wilson et al, 2009). Together with our observations
of excessive pSTAT3 accumulation in human IPF biopsies, these
recent ﬁndings further strengthen a rationale to exploit Stat3 as
an attractive signalling node for novel therapeutic strategies for
IPF.
Here, we provide genetic evidence for the capacity of Stat3
to link signalling from IL-6 family cytokines to stimulation
of Col1a1 expression and parenchymal collagen deposition
independently of canonical TGF-b/Smad3 signalling. Previous
reports have described the capability of IL-6 to stimulate
collagendepositionintheskinandhaveidentiﬁedputativeStat3
binding sites in the Col1a1 and Col3a1 promoters (Lim et al,
2006). Consistent with this, we observed reduced bleomycin-
induced ﬁbrosis in the absence of IL-6 and that gp130-mediated
increase in collagen gene reporter activity in ﬁbroblasts was
dependent on Stat3. By contrast, transgenic expression of IL-6
in the Clara cells of the uninjured mouse lung was associated
with airspace enlargement in older mice (Kuhn et al, 2000),
reminiscent of the distinct emphysematous and inﬂammatory
changes in lungs of naı ¨ve 6 months old gp130
757F mice
(Ruwanpura et al, 2011). Although the gp130
757F mice used in
this study were less than 3 months old and occasionally showed
mild air space enlargement (Fig 1; Ruwanpura et al, 2011), there
was no evidence for increased IL-6 levels (Fig 2D and Supporting
Information Fig S4A) at this stage. Since IL-6 expression rapidly
increased after bleomycin challenge, we surmise that excessive
IL-6 within the injured lung promotes ﬁbrosis.
Although the development of experimental lung ﬁbrosis
in wild-type mice is inhibited in the absence of canonical
TGF-b/Smad3 signalling (Bonniaud et al, 2004; Zhao et al,
2002), the protective effect arising from its ablation is overcome
in situations of excessive Stat3 activation that results from
mutant gp130
757F receptors during bleomycin-induced lung
injury or from the sustained presence of IL-6 family cytokines,
including Osm. Although the inﬂammatory response elicited
by systemic LPS administration induces the production of the
transcriptionally active Smad2 splice variant Smad2
DExon3
(Dunn et al, 2005), which can replicate Smad3 transcriptional
activity (Yagi et al, 1999), it remains unknown whether
Smad2
DExon3 can mediate activation of the Col1a1 gene
promoter. Notwithstanding that canonical TGF-b signalling
integrates various inﬂammatory and regenerative stimuli that
promote wound healing and the deposition of de novo tissue
matrix, our data provide a strong rationale for targeting the
gp130/Stat3 signalling axis as a complementary approach to
current clinical trials focusing on components of the TGF-b
signalling cascade.
MATERIALS AND METHODS
Mice and treatments
All mutant gp130
DStat and gp130
757F mice along with their
corresponding Stat3
þ/ , Stat1
 / , Il6
 / , Rag1
 / , mMT
 /  or
Smad3
 /  counterparts were between the ages of 8 and 12 weeks
and were propagated on a mixed 129/Sv C57BL/6 genetic back-
ground (Ehlich et al, 1993; Ernst et al, 2008; Jenkins et al, 2005a;
Tebbutt et al, 2002). All animals were housed under specific pathogen-
free conditions and experimentation was approved by the Institute’s
Animal Ethics Committee.
We transnasally delivered a bolus of 50ml bleomycin (0.05U/mouse;
Blenoxane, Bristol-Myers Squib, New York, USA), or 2mg HYPER-IL-6
every second day for 14 days to anaesthetized mice. We trans-nasally
delivered 5 10
7 PFU adenoviral vector in 30ml PBS and collected
lungs 14 days later (Langdon et al, 2003). Lethally irradiated mice
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Figure 6. Stat3 haploinsufficiency prevents lung fibrosis.
A. Masson’s trichrome stained section of lungs for wild-type (wt), Il6
 / 
(Il6
 / ) and Stat3
þ/  (Stat3
þ/ ) mice 30 days after saline or bleomycin
treatment. Images are representative of two mice. Scale bar¼500mm
(¼100mm insets).
B. Percent change in hydroxyproline content in lung homogenates between
saline and bleomycin-treated mice of the indicated genotypes 30 days
after challenge. Data are expressed as mean percentage change SEM,
with
 p<0.05. n¼5 mice. The range of collagen levels between saline and
bleomycin treated mice was 4.442–14.070mg.
948  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2012) 4, 939–951were reconstituted with bone marrow (Ernst et al, 2008) at least
30 days before challenging with bleomycin. BAL fluid was collected by
endotracheal instillation of three 0.4ml aliquots of PBS to recover
approximately 1ml of fluid, pelleted cells were stained with Quik-Dip
(Scot Scientific, Taren Point, Australia) and differential cell counts
performed.
Cytokines, plasmids and antibodies
The pCol1a1-luc and p(CAGA)12-luc constructs and the production of
HYPER-IL-6 has been described (Buttner et al, 2004; Fischer et al,
1997). Recombinant human IL-6 and human TGF-b1 were from
Bender Medsystems (Vienna, Austria) and Sigma–Aldrich (St Louis,
USA), respectively. Antibodies directed against B220 were from Becton
Dickinson Biosciences (San Jose, USA), CD3 from Serotec (Kidlington,
UK), F4/80 from Abcam (Cambridge, UK), a-tubulin (Sigma–Aldrich),
CD45 and cytokeratin AE1/AE3 from Dako (Glostrup, DK), phosphory-
lated Stat3 (Cell Signaling Technology, Danvers, USA) and b-actin,
Stat3 or phosphorylated Smad3 (Santa Cruz Biotechnology).
Collagen quantification, lung fibroblast preparation and
cellular assays
We analysed hydroxyproline content of lung homogenates as
described (Mutsaers et al, 1998). We digested lungs in 0.25%
trypsin-EDTA (Invitrogen Life Technologies, Carlsbad, USA) at 378C
for 30min and removed remaining connective tissue. Digests were
finely minced and incubated in 1mg/ml collagenase 1 (Invitrogen
Life Technologies) for 1h at 378C. Pelleted cells were used for
establishing primary lung fibroblast cultures in DMEM (Invitrogen
Life Technologies) supplemented with 10% foetal bovine serum
(Sigma–Aldrich, Castle Hill, Australia), 4mM L-glutamine (Invitrogen
Life Technologies) and penicillin–streptomycin–fungizone cocktail
(Invitrogen Life Technologies), and assays were performed on passage
3–5 cells. We exposed embryonic fibroblasts, co-transfected with
pCol1a1-luc and the pCMV-Rluc plasmid to HYPER-IL-6 and
determined dual luciferase activity in triplicate cultures 48h later
(Jenkins et al, 2005a).
RNA isolation and expression analysis
We extracted total RNA from tissues or snap-frozen cell cultures with
TRIzol (Invitrogen Life Technologies) and prepared cDNA from 1mgo f
total RNA using the SuperScript III System (Invitrogen Life Technol-
ogies). We performed quantitative RT-PCR analysis on lung tissues in
triplicate with the iCycler platform (Bio-Rad Laboratories, USA) using
SYBR Green (Invitrogen), and quantified Col1a1 (forward 50-GGAA-
GAGCGGAGAGTACTGG-30, reverse 50-GTACTCG AACGGGAATCCAT-30), Il6
(forward 50-GTATGAACAACGATGATGCACTTG-30, reverse 50-ATGGTACTC-
CAGAAGACCAGAGGA-30), Il11 (forward 50-CTGCACAGATGAGAGACA
AATTCC-30, reverse 50-GAAGCTGCAAAGATCCCAATG-30) Osm (forward
50-AACACTGC TCAGTTTGACCCTCAGT-30, reverse 50-AGGTTTTGGAGGCG-
GATATAGGGCT-30), Socs3 (forward 50-GCGGGCACCTTTCTTATCC-30,
reverse 50-TCCCCGACTGGGTCTTGAC-30) transcripts using glyceral-
deyhde-3-phosphate-dehydrogenase (Gapdh)( f o r w a r d5 0-TCGG
TGTGAACGGATTTGGC-30, reverse 50-GAATTTGCCGTGAGTGGAGT-30)o r
18S (forward 50-GTAACCCGTTGAACCCCATT-30,r e v e r s e5 0-CCATC-
CAATCGGTAGTAGCG-30) as a housekeeping gene (Scaffidi et al, 2002).
Each RNA sample was analysed in duplicate.
Immunohistochemistry
We stained consecutive 5mm sections of inflated (250mm-H2O
pressure), paraformaldehyde-fixed and paraffin-embedded lungs with
haematoxylin and eosin, Masson’s trichrome (staining collagenous
deposits green), or for the cell lineage markers B220, CD3, F4/80 or
phosphorylated Stat3. We characterized inflammatory foci as a
collection of granulocytic and/or lymphocytic cells that occupied at
least one field of view (20  objective lens), and within these foci
counted the total number of indicated cells from three or more
randomly chosen sections from each tissue block. Paraffin embedded
human tissue was immunolabelled for the cell lineage markers
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The paper explained
PROBLEM:
Idiopathic pulmonary fibrosis (IPF) is a heterogeneous disease
with an incidence of approximately 1 per 10,000, equivalent to
many cancers, and which is unresponsive to therapy and fatal in
outcome. Although fibrosis is thought to arise from excessive
tissue response to injury, the molecular mechanisms underlying
the initiation of IPF remain largely unknown.
RESULTS:
In the present study we utilize mutant mice carrying engineered
mutations in gp130, the interleukin (IL)-6 co-receptor, to provide
genetic evidence for the causal involvement of IL-6-dependent
Stat3 signalling in this disease in an established preclinical
setting. Using a genetic complementation approach, we define a
functionalrequirementforIL-6,Stat3andmatureB-lymphocytes
for the development of disease. Significantly, we provide genetic
and biochemical evidence that Stat3-driven lung fibrosis can
occur by a mechanism independent of signalling through the
canonical transforming growth factor (TGF)-b/Smad3 pathway.
We also document excessive Stat3 activation as a common
feature in human patients with IPF and provide evidence that
reduction of systemic Stat3 expression in mice decreases
susceptibility to bleomycin-induced fibrosis.
IMPACT:
Previous studies have demonstrated that canonical TGF-b/
Smad3 signalling is pivotal to the pathogenesis of pulmonary
fibrosis. Our study demonstrates that that therapeutic targeting
of IL-6/Stat3 signalling and/or B-lymphocytes may ultimately
afford more efficacious treatments for IPF and related diseases
than those directed solely against TGF-b/Smad3 signalling.
EMBO Mol Med (2012) 4, 939–951  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 949pan-cytokeratin, CD45 and phosphorylated STAT3 following antigen
retrieval with 10mM citrate buffer pH6.
Patient samples
Tissue biopsies from four male patients with diagnosed IPF-UIP (age
range of 59–69 years, mean of 63 years) and appropriate controls
were used in this study. Human ethics approval for this study
was provided through Bellberry Limited for work carried out at Sir
Charles Gairdner Hospital, W.A., Australia. All human samples used in
this study were retrospective paraffin embedded tissue samples taken
for diagnostic purposes. The collection and use of these samples for
this study was consistent with Section 3.2.4 of the National Health
and Medical Research Council of Australia, Australian Health Ethics
Committee guidelines for research involving humans and Section 25
of the World Medical Association, Declaration of Helsinki.
Statistical analysis
Data are expressed as mean SEM, with
 p<0.05,
  p<0.01,
   p<0.001. Statistical analysis was performed using one-way
analysis of variance and Bonferroni’s multiple comparisons post-test.
For more detailed Materials and Methods see the Supporting
Information.
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